Phase 2 Major Depressive Disorder trials recruiting now

All Major Depressive Disorder trials, every phase

Other phases for Major Depressive Disorder

Phase 2 Major Depressive Disorder trials

• 5-HTP and Creatine for Depression R33 Phase
  NCT05895747 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
  NCT06820723 · Phase: Phase 2 · Ages: 21 Years to 65 Years · Sex: All (male and female) · 1 location
• A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT07115329 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 32 locations
• A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD
  NCT06236880 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Randomized Neuroimaging Trial of Psilocybin in Depression
  NCT06072898 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
  NCT07276997 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 33 locations
• Imaging Depression in Parkinson's Disease
  NCT06402955 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• JAK Signaling in Depression
  NCT07003997 · Phase: Phase 2 · Ages: 25 Years to 55 Years · Sex: All (male and female) · 1 location
• Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
  NCT06559826 · Phase: Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
  NCT06529029 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Maternal Mental Health Trial
  NCT04685148 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 45 Years · Sex: Female · 1 location
• Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial
  NCT06626152 · Phase: Phase 2 · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• Mindfulness Engaged Neurostimulation for Depression (MEND II)
  NCT07512284 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
  NCT05136755 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• NMDA Modulation in Major Depressive Disorder
  NCT04637620 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Neural Response to Inflammatory Challenge in Major Depressive Disorder
  NCT04751331 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
  NCT05570812 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 2 locations
• Neutralizing Interleukin (IL)-6
  NCT07493317 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
  NCT07185815 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 6 locations
• Pharmacologic Treatment Augmentation in Chronic Depression
  NCT06410599 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 2 locations
• Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
  NCT06592833 · Phase: Phase 2 · Ages: 21 Years to 80 Years · Sex: All (male and female) · 1 location
• Psilocybin rTMS for Treatment Resistant Depression
  NCT06132178 · Phase: Phase 2 · Ages: 22 Years to 65 Years · Sex: All (male and female) · 1 location
• Regulation of Affect and Physiology in Depression
  NCT06345859 · Phase: Phase 2 · Ages: 18 Years to 27 Years · Sex: All (male and female) · 1 location
• Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
  NCT06376734 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 6 locations
• Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
  NCT05757791 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
  NCT06633016 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 50 locations
• Study of ALTO-300 in MDD
  NCT05922878 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 45 locations
• Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
  NCT00018057 · Phase: Phase 2 · Ages: 8 Years to 65 Years · Sex: All (male and female) · 4 locations
• The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
  NCT05786066 · Phase: Phase 2 · Ages: 21 Years to 65 Years · Sex: All (male and female) · 1 location
• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT06547489 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 34 locations
• i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
  NCT06480500 · Phase: Phase 2 · Ages: 21 Years to 65 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.